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The most remarkable example is Kymriah, a chimeric antigen receptor T-cell (CAR-T) therapy that 33 was approved recently as the first cell-based gene therapy in the United States 2 .
34
The major technical challenge in cell engineering is to confer new properties to the manipulated 35 cells with little interference with the cells' endogenous functions. As the most common and robust 36 cell-engineering approach, genetic engineering is limited by technical complications and safety 37 concerns (Fig. 1A) , such as the viral transduction resistance of primary cells, heterogeneous 38 expression levels, and the potential for endogenous gene disruption [3] [4] [5] . Therefore, engineering cell 39 surfaces from "outside" has emerged as a complementary and generally-applicable approach 6,7 .
40
Preeminent examples include metabolic oligosaccharide engineering (MOE) developed by Bertozzi, 41 et al. (Fig. 1A) and sortagging, the transpeptidation reaction catalyzed by bacterial sortases, among 42 others 6, [8] [9] [10] . MOE requires a two-step procedure, combining metabolic labeling with bioorthogonal 43 chemistry to endow cell-surface glycans with new functions. Sortagging involves only a single-step 1 treatment. However, cells without genetic modification only have a few thousand naturally exposed 2 glycine residues that can be functionalized by this approach 11 . Therefore, direct functionalization of 3 the cell surface in a non-invasive and highly efficient way is still difficult to achieve 6, 10 . Cell 4 engineering would benefit from a single-step method that efficiently modifies native substrates on the 5 surfaces of cells to incorporate novel functionalities. 6
In situ glycan editing via glycosylation enzymes is a single-step approach to modify glycocalyx. 7
The most notable example of its application is ex vivo fucosylation of mesenchymal stem cells and 8 regulatory T cells using GDP-fucose (GDP-Fuc or GF) and recombinant human 9 α(1,3)-fucosyltransferase (FucT or FT) VI 12,13 . This procedure, currently undergoing several clinical 10 trials, improves adhesion, homing, and engraftment of adoptively-transferred cells. However, 11 enzymatic glycoengineering has not been widely used in therapeutic interventions 6 . A major 12 limitation is that current enzymatic transferrable substrates are confined to small, synthetic molecules 13 (MW <2000) [14] [15] [16] , while biomacromolecules (e.g. monoclonal antibodies, mAbs) that have high 14 therapeutic value are not accessible.
15
Here, we report the discovery of the remarkable substrate tolerance of H. pylori α1,3FucT. This 16 enzyme enables quantitative transfer of a full length IgG antibody conjugated to the GDP-Fuc donor 17
to LacNAc (Galβ1,4GlcNAc), a common building block of glycocalyx, on the cell surface of live 18 cells within a few minutes (Fig. 1B) . A one-pot protocol that couples the synthesis of an unnatural 19 GDP-Fuc derivative to the subsequent derivative transfer was developed and made this engineering 20 approach practical and cost effective. Using this technique, we constructed two types of antibody-cell 21 conjugates (ACCs) using a natural killer cell line (NK-92MI) and primary CD8+ OT-1 T cells. We 22 demonstrated, for the first time, the application of this technique to boost the activities of modified 23 immune cells, including specific tumor targeting and resistance to inhibitory signals produced by 24 tumor cells.
26
Results and discussion 27 28 A one-pot protocol for preparing and transferring GDP-Fuc derivatives 29
To develop the enzyme-based glycan modification as a general method for cell-surface 30 engineering, a practical and scalable approach for the preparation and transfer of nucleotide sugar 31 donors equipped with new functional groups is required 17 . We discovered that 32 GDP-L-6-ethynylfucose (GF-Al) or GDP-L-6-azidofucose (GF-Az) produced in situ can be coupled 33 directly with a wide variety of probes using the ligand accelerated copper(I)-catalyzed alkyne-azide 34 cycloaddition (CuAAC) [18] [19] [20] (Fig. 1C) . These probes include biotin, a fluorescent probe Cy3, a 35 bioorthogonal reaction handle tetrazine (Tz) and a dye (fluorescein amidite, FAM) labeled, 36 single-strand DNA (ssDNA) (Supplementary Fig. S1 ). All reactions attained near quantitative yields 37 (> 90%), and the crude products were rendered biocompatible for direct transfer by α1,3 FucT onto 38 the cell surface after quenching the reaction with the FDA-approved copper chelator bathocuproine 39 sulphonate (BCS) (Supplementary Fig. S2 ). Compared to the conventional two-step labeling 40 protocol 15 , i.e. enzymatic transfer followed by cell surface click chemistry, the one-step enzymatic 41 labeling using the substrate of one-pot product was significantly more efficient and biocompatible 42 (Supplementary Fig. S3 ). In addition, we found that the enzymatic transfer of the one-pot Tz 43 derivative made from GF-Az was more efficient than that made from GF-Al ( Supplementary Fig.  1 
S2D). 2
Sortagging is probably the best known enzymatic covalent ligation reaction without the need for 3 genetic manipulation of the target cell population. We directly compared the efficiency of the 4
FucT-mediated cell-surface modification with that catalyzed by sortase (SrtA 5M) using 5 biotin-conjugated substrates. At the optimal substrate concentration (500 µM of biotin-LPETG), 6 negligible transpeptidation reaction took place within 2 hr in the presence of 1 µM of sortase 7 (Supplementary Fig. S4A ). By contrast, 0.6 µM of FucT afforded robust cell-surface labeling within 8 2 min in the presence of 50 µM of GDP-Fuc-biotin (Supplementary Fig. S4B ). Even at 20 µM 9 enzyme concentration, it took 120 min for sortagging to reach signal saturation 21 . Moreover, when 10 0.6 µM of FucT and 20 µM sortase were used for cell-surface modification, respectively, the 11
FucT-catalyzed process was found to be at least 80 times more efficient than the sortase-catalyzed 12 process (Supplementary Fig. S4A ).
14
Enzymatic transfer of full-length IgG molecules to the cell surface using FucT 15 16
The remarkable efficiency of fucosylation to transfer small-molecule probes with diverse 17 structures to the cell surface combined with the previous known plasticity of mammalian 18 sialyltransferases for protein PEGylation 22 suggests the possibility that FucT may tolerate even larger 19 molecules conjugated to the fucose C6 position. To assess this possibility, we conjugated 20 GDP-fucose with monoclonal antibodies (mAbs, full length IgG), the fastest growing class of protein 21 drugs. The bioorthogonal handle trans-cyclooctene (TCO) with a PEG linker was installed onto 22 mAbs or their isotype controls via standard amine-coupling procedures 23 . Subsequently, mAbs 23 bearing TCO moieties were reacted with GF-Az-Tz via the inverse electron-demand Diels-Alder 24 reaction (IEDDA) 24 to generate GDP-Fuc-conjugated IgG molecules (GF-IgG) ( Fig. 2A) . GDP-Fuc 25 modified antibodies were characterized by MALDI-TOF MS and were found to exhibit similar 26 antigen binding capacities compared to their parent antibodies (Supplementary Fig. S5 ).
27
The one-pot product of GDP-Fuc conjugated rat IgG (GF-rIgG) was then incubated with Lec2 28 CHO cells that express abundant terminal LacNAc units in the presence of FucT (Fig. 2B) .
29
Remarkably, the signal of rIgG conjugated onto the cell surface was detectable after a 2-min 30 incubation with FucT (60 mU) and GF-rIgG (0.1 mg/ml) (Fig. 2C) . The labeling efficiency was 31 concentration-dependent (GF-rIgG), which reached saturation at 0.1 mg/ml (Fig. 2D) . Notably, the 32 conjugation reaction was completed in 10 minutes even on ice (Fig. 2E) . At the saturated condition, 33 approximately 2.5×10 5 rIgG molecules were introduced to the cell surface ( Fig. 2F and  34 Supplementary Fig. S6A ). The viability of the rIgG-labeled cells was similar to that of unlabeled 35 cells, which further confirmed the biocompatibility of this one-pot procedure ( Supplementary Fig.  36 S7). Lec8 CHO cells, which do not express LacNAc, were used as a negative control to confirm that 37 the transfer was dependent on the reaction between the GDP-Fuc derivative and cell-surface LacNAc.
38
As expected, only background fluorescence was displayed by the Lec8 cells after the enzymatic 39 reaction (Fig. 2G) . A competition experiment using cells blocked by natural substrates of FucT, i.e., 40 GDP-Fuc, also was conducted, and the subsequent GF-rIgG labeling almost was abolished 41 (Supplementary Fig. S8 ). These results confirmed that the reaction sites of enzymatic transfer of 42 GF-rIgG were the same as those for GDP-Fuc on the surface of the cell. Furthermore, confocal 43 microscopy analysis verified that most of the labeled rIgGs were located on the cell membrane ( Fig.  1  2H) . Importantly, multiple functionalities can be introduced to the surface of the cell simultaneously, 2 e.g., two antibodies (GF-rIgG and GF-mIgG-GDP-Fuc modified mouse IgG) ( Fig. 2I and  3 Supplementary Fig. S9) . Such results are difficult to achieve via genetic approaches. Worthy of note, 4
ACCs can also be built using recombinant sialyltransferases and CMP-Sialic acid-antibody 5 conjugates though with much less efficiency (Supplementary Fig. S10 ). 6
This approach was equally efficient to modify primary human cells, e.g. T cells; robust labeling 7 with IgGs was achieved within 15 min ( Supplementary Fig. S11 and S6B ). We confirmed that the 8 bioconjugation of IgG molecules to the cell surface had no short-term interference with the 9 expression of cell surface markers (Supplementary Fig. S12 ). The half-life of IgG molecules 10 conjugated to the cell surface is approximately 24 hours, and the conjugation had no effect on the 11 proliferation of the modified cells ( Supplementary Figs. S11C and S11D) .
12
Taken together, we confirmed that the transfer of GF-IgG to LacNAc on the cell surface via 13
FucT is a highly efficient one-step approach to construct ACC. (Fig. 3A) . We chose, NK-92MI cells, an IL-2 independent 26 variant of the NK-92 cell line, as the candidate for bioconjugation with Herceptin because it 27 constantly expresses a high level of LacNAc to be modified by GDP-Fuc conjugated human IgG 28 (GF-hIgG) (Supplementary Fig. 13A ). Herceptin, also known as Trastuzumab, is used extensively to 29 treat human epidermal growth factor receptor 2-positive (HER2+) breast cancer. We calculated that 30 approximately 3×10 5 Herceptin molecules were conjugated to the surface of a NK-92MI cell, which 31 equaled to ~7.5 ng Herceptin/0.1 million cell (Supplementary Fig. S6C ). Herceptin conjugated to 32 the surface of NK-92MI cells maintains exclusive binding to the HER2 antigen ( Fig. 3B and  33 Supplementary Figs. 13B and 13C), and its cell-surface half-life is approximately 20 h 34 (Supplementary Fig. 13D ). As revealed by flow cytometry analysis and confocal imaging NK-92MI 35 cells conjugated with Herceptin had strong interactions with BT474-a HER2+ breast cancer cell-36 in a co-culture assay, whereas unmodified NK-92MI cells were only weakly bound (Figs. 3C and 37 3D). Moreover, NK-92MI cells modified with Herceptin induced the lysis of BT474 cells more 38 effectively than unmodified NK-92MI cells (Fig. 3E) . Neither isotype control hIgG labeling nor 39 co-treatment with excess free Herceptin (1000 ng/0.1 million NK cells) could enhance the killing 40 activity of NK-92MI on BT474, indicating that covalent conjugation of Herceptin to the surface of 41 NK-92MI cells is required (Fig. 4E) . Importantly, the cell-lysis efficiency of the modified NK-92MI 42 cells also was dependent on the loading of GF-Herceptin on the cell surface, which reached the 43 plateau when 0.1mg/mL of GF-Herceptin was used for bioconjugation (Fig. 3F, Supplementary Fig.  1  14) . The enhanced killing effect of Herceptin-NK92-MI conjugates later was confirmed on other 2 HER2+ cancer cells, including SKBR3 and MDA-MB-435/HER2+, but not on HER2 negative 3 (HER2-) cancer cells, such as MDA-MB-435 and MDA-MB-468 (Fig. 3G) . In addition, the total 4 secretion of granzyme B increased only when Herceptin-NK-92MI conjugates was mixed with 5 BT474 (Supplementary Fig. 13E ), indicating that the Herceptin-HER2 binding induced proximity 6 between the modified NK-92MI cells and target cells promoted the cancer-cell triggered NK-92MI 7 cell activation. Similar to other cell-mediated cytotoxicity, higher effector-to-target cell ratios also 8 have better killing results, but only in the Herceptin-labeled NK-92MI group, which reaches 9 saturation at 5:1 (Fig. 3H) . Another distinct advantage of enzymatic cell engineering is that several 10 antibodies can be conjugated onto the surface of a cell at the same time. As proof-of-concept, we 11 conjugated NK-92MI cells with both of Herceptin and an anti-EGFR antibody ( Supplementary Fig.  12 15), and the duel modified cells exhibited better killing efficiency on SKOV3 cells (HER2+EGFR+) 13 than that induced by the single-mAb modified counterparts (Fig. 3I ).
14
The promising results of enhanced ex vivo killing ability of Herceptin-NK92-MI conjugates led 15 us to test their efficacy in vivo. Since NK-92 is developed from a patient with lymphoma, as a safety 16 measure, it is usually irradiated prior to clinical use to prevent permanent engraftment in human body.
17
As expected, irradiation of 6 Gy prevented the proliferation of NK-92MI cells ( Supplementary Fig.  18 16A). We found gamma irradiated NK-92MI cells maintained their cytotoxicity (Fig. 3J ) and the 19 half-life of Herceptin conjugated to irradiated NK-92MI was slightly longer than that of the 20 non-irradiated group (Supplementary Fig. 16B ). on day 3 and day 9. Bioluminescence imaging showed that tumor cell growth was significantly 37 suppressed by Herceptin-labeled NK-92MI cells compared to unmodified NK-92MI cells 38
( Supplementary Fig. 17 ). 39 40
Anti-PD-L1 (α-PD-L1) conjugated on the surfaces of cells could block the PD-1/PD-L1 pathway 41
and enhance the proliferation of T cells ex vivo.
42
Even after infiltrating the tumor bed, cytotoxic functions of effector cells may be dampened by 43 factors produced in the microenvironment of the tumor 27 . As another application of our new 1 technique, we sought to determine whether CD8+ T cells modified by cell-surface mAb conjugation 2 could counteract such inhibitory signals to maintain their activities. The interaction between 3 programmed death 1 (PD-1) receptor, found on T cells, and PD-Ligand (PD-L) expressed by tumor 4 cells plays a major role in inhibiting the cytotoxicity of T cells 28 (Fig. 4A) . We hypothesize that the 5 installation of α-PD-L1 on the surfaces of T cells may block the PD-1/PD-L1 interaction in situ to 6 enhance the activation of the T cells and thus enforcing tumor cell lysis (Fig. 4B ). 7
OT-1 transgenic mice was chosen as the model system whose CD8+ T cells express a T cell 8 receptor (TCR) specific for the SIINFEKL peptide (OVA 257-264 ) of ovalbumin presented on MHC I. 9
Splenocytes from the OT-1 mice were first stimulated with OVA 257-264 peptide and expanded ex vivo 10 in the presence of IL2 or IL7/IL15. After three days, most of the cells are activated OT-1 CD8+ T 11 cells (Supplementary Fig. 18A ). During the next 10 days, OT-1 T cells were confirmed to express 12 high levels of LacNAc ( Supplementary Fig. 18B ) and were subjected to the chemoenzymatic 13 modification with GF-rIgG ( Supplementary Fig. 18C ). Re-stimulation experiments confirmed that 14 the modified T cells had a similar proliferation rate to that of the unmodified cells, suggesting that the 15 conjugated IgG molecules do not block the interaction between TCR and the MHC I-complex 16
( Supplementary Fig. 18D ). Fig. S6D ). Then, the modified OT-1 CD8+ T cells were subjected to an 25 ex vivo killing assay, in which a B6-derived melanoma cell line B16F10 expressed ovalbumin 26 (B16-OVA) was used as model target cells. After incubation for 20 hours, the OT-1 T cells 27 conjugated with α-PD-L1 showed significantly enhanced lysis of B16-OVA cells (Fig. 4E) , and the 28 enhanced killing effect was observed only when the effector-to-target cell ratio was above 1 (Fig. 4F) .
29
By contrast, the specific lysis of B16-OVA induced by the rIgG-OT-1 T cell conjugates was much 30 weaker, which is similar to that of the control, unmodified T cells (Fig. 4E) . CD8+ T cells of 31 irrelevant specificity from P14 mice also were conjugated with α-PD-L1 as a negative control. 32
Remarkably, this ACC only induced background killing ( Fig. 4E) , suggesting that trace levels of 33 α-PD-L1 conjugated to the surfaces of the cells could not mediate significant target cell lysis.
34
Although the antigen binding capacity reached the maximum when 0.1 mg/ml GF-α-PD-L1 was used 35 for cell-surface conjugation (Fig. 4D) , the optimal killing capacity was achieved at ~ 0.05 mg/ml 36 GF-α-PD-L1 ( Fig. 4G) , suggesting that only half of the maximum cell-surface conjugation is 37 required for efficient blocking the PD-1-PD-L1 interaction. Moreover, using the same killing assay 38
we observed that α-PD-L1-modified OT-1 cells exhibited significantly better lysis capability than a 39 simple combination of OT-1 cells with free α-PD-L1 (Fig.4H ).
40
To further determine whether the cell-surface conjugated α-PD-L1 could suppress PD-1/PD-L1 41 co-inhibitory signaling, we measured the cytokine produced by modified OT-1 T cells when they 42
were mixed with B16-OVA. The enhanced IFN-γ and TNF-α secretion only was observed in T cells 43 conjugated with α-PD-L1, which exhibited dependency on the dosage of conjugated α-PD-L1 ( Fig.  1 4I and Supplementary Fig. 20) . The enhanced T-cell activation also was observed directly using 2 microscopy due to the formation of larger clusters of T cells in the α-PD-L1 labeled group (Fig. 4J  3 and Supplementary Fig. 21A ). Finally, the enhanced activation of T cells also promoted T cell 4 proliferations as confirmed by a CFSE dilution assay by re-stimulating modified OT-1 T cells with 5 B16-OVA ( Fig. 4K and Supplementary Fig. 21B ). 6 7 Conclusion 8
The one-step FucT-based chemoenzymatic method developed here is a fast, simple, and 9 cost-effective technique for cell engineering, especially for constructing ACCs. proliferation after the activation mediated by B16-OVA through CFSE dilution. Mean ± SD (error 18 bars); .In all figures, ns, P > 0.05; ** P < 0.01; *** P < 0.001; **** P < 0. Alexa Fluor 647 NHS Ester, cell tracker green (CMFDA) and orange (CMTMR) were 29 purchased from Thermo Fisher Scientific. 5×RIPA buffer kit were purchased from CellBiolabs, Inc. CytoTox 96® non-radioactive cytotoxicity assay and Bright-Glo™ 1 luciferase assay system were purchased from Promega Corporation. Inorganic 2 pyrophosphatase, FKP and FucT were expressed in endotoxin free bacteria (ClearColi® 3 BL21-DE3, Lucigen) and purified as previously reported 1 . Pure GDP-Fuc, GF-Al and 4 BTTP were synthesized as previously described 1, 2 . The plasmid of Sortase A (5M) is a 5 kind gift from Prof. Peng Chen (PKU). The enzyme was expressed and purified 6 according to their work 3 . 7
Equipment 8
All of the flow cytometry analyses were performed on an Attune NxT Flow Cytometer. 9
Images of protein gels including coomassie SDS-PAGE gel and western blotting 10 membrane were taken on ChemiDoc XRS+ (Bio-Rad). Absorbance, fluorescence 11 intensity and luminescence were monitored in a Multi-Mode Microplate Reader 12 (Synergy TM H4, Bio-Tek). Confocal images were taken on a Nikon spinning disk 13 confocal microscope (TE2000). Fluorescent and phase contrast microscope images were 14 taken on an All-In One fluorescence microscope (Keyence, BZ-X700). Bioluminescence 15 imaging of live mice were acquired using an IVIS Spectrum system. 16
Cells 17
Cell lines were all purchased from ATCC unless otherwise specified. RPMI 1640 (GlutaMAX) with 10% heat-inactivated FBS, 1 mM sodium pyruvate, 50 µMβ-ME, 10mM HEPES and 1×MEM NEAA (GIBCO) (referred as T cell culture media 1 later). Cytokines in T cell culture media were added as indicated (rhIL2, rhIL7 and 2 rhIL15 are all from NIH program). All cells cultures were incubated at 37 o C under 5% 3 CO 2 . 4
Mice 5 All mice were bred or housed under specific pathogen free (SPF) conditions. All animal 6 experiments were approved by TSRI Animal Care and Use Committee. OT-1 mice are 7 purchased from Taconic Biosciences. CD 45.1 mice from C57BL/6J (B6) genetic 8 background were purchased from the Jackson Laboratory. The strain of OT-1+/-/CD 9 45.1+/-was generated by cross breeding. Six female B6 background P14 mice were gifts 10 from Prof. John Teijaro lab. 176 female NSG mice are gifts from Prof. Philippe A. Gallay 11 lab. Both male and female mice of 8-20 weeks of age were used for most experiments. 12 13 Supplementary Methods 14
One-pot protocol for producing GDP-Fuc derivatives 15
Reactions were typically carried out in a 15 mL corning tube with 5 mL 100 mM HEPES 16 buffer (pH 7.5) containing L-fucose analogues (final concentration, 10 mM), ATP (10 17 mM), GTP (10 mM), MgSO 4 (10 mM), KCl (50 mM), inorganic pyrophosphatase (90 18 units, ~0.17 g/L, endotoxin free), and FKP (9 units, ~0.6 g/L, endotoxin free). The 19 reaction mixture was incubated at 37 °C for 5-6 h with shaking (225 rpm). After the 20 reaction finished (monitored by TLC analysis 1 ), enzymes were precipitated by adding 5 21 mL cold EtOH into the crude product. After the precipitates were removed through 22 centrifuge (8000×g, 5 min), the crude products (containing ~10 mM GDP-Fuc analogues) 23 could be directly used. For GF-Al and GF-Az, further modification could be achieved 24 through CuACC reaction. Crude GF-Al/GF-Az sample (~5 mM, in HEPES buffer) were 25 reacted with azide/alkyne probes (6 mM) in the presence of Cu/BTTP (1/2, 500 µM) and 26 sodium ascorbate (2 mM) at 30 °C for 6h (For Tz substrates, add one volume of MeOH in 27 reaction mixture). After reaction finished (monitored by TLC and LC-MS analysis, 28 representative figures of GF-Az-Tz and GF-Al-Tz are shown in Spectra part), BCS(bathocuproine sulphonate, 2 mM) were added to quench the reaction. These 1 biocompatible crude products were lyophilized and reconstituted in pure water to a final 2 concentration of 10 mM, which could be directly used in cell labeling. Following this 3 protocol, we made one-pot products of GF-Al-Biotin, GF-Al-Cy3, GF-Al-Tz and GF-Az-4
Tz. Their structures are shown in Figure S1 . Since GF-Al-Tz and GF-Az-Tz are 5 important starting materials for making GF-IgG, we purified these two GDP-fucose 6 derivatives and characterize them using high-resolution ESI-TOF MS and NMR 7 (Spectra), which also confirm the one-pot procedure is reliable. 
Preparation of GDP-Fuc modified antibodies 26
All of the antibodies (full-length IgG, MW: ~150 KDa) for conjugation were first 27 desalted into PBS and concentrated to a 6 mg/mL solution. TCO group was first 28 introduced onto antibodies according to the standard labeling protocol of TCO-PEG4-1 NHS ester (https://clickchemistrytools.com/product/tco-peg4-nhs-ester/) and previous 2 reports 5,6 about its application on IgG labeling. Briefly, we prepared fresh 50 mM stock 3 of TCO-PEG4-NHS reagent in DMSO and add it to the IgG sample (final concentration 6 4 mg/mL) at a final concentration of 0.5 mM. The reactions were incubated at room 5 temperature for 30 minutes and quenched by adding Tris buffer (pH 8.0) to a final 6 concentration of 50mM Tris. The quenched reaction mixtures were incubated at room 7 temperature for 5 minutes and then desalted into PBS using G25 desalting column (PD-8 10, GE). The concentrations of desalted TCO-IgGs were around 4.5 mg/mL (~1-4 TCO 9 per IgG). After that, ~10 mM one-pot products of GF-Az-Tz were added to TCO-IgGs 10 with a final concentration at 0.15 mM (5eq of IgG). After 30 minutes of incubation at 11 room temperature, these one-pot GF-IgG products were ready to use and could be kept at gel imaging analysis, GF-IgG-A647 was used instead of GF-IgG. At the saturated 6 labeling condition, labeled cells and control cells were collected and lysed in SDS 7 loading buffer and subjected to SDS-PAGE analysis. Pure GF-IgG-A647 proteins were 8 also loaded as standards in quantification. 9
Primary human T cells preparation and IgG labeling on their surface 10
Fresh PBMCs were freshly prepared as described above. 4 million per mL PBMCs were 11 cultured in T cell culture media with 15 ng/mL rhIL2 and activated with human 12 CD3/CD28 T cell activator for two days. After that, activated human T cells were kept 13 under 4*10 6 cells/mL in T cell culture media (fresh media with cytokine were added 14 every two days). Phenotypes were characterized after two weeks expansion (>95% are 15 human T cells). LacNAc levels on CD4+ and CD8+ T cells were tracked through 16 fucosylation with GF-biotin on day 0 (naïve T cells), day 2, day 4, day 7, day 11 and day 17 13. Activated human T cells were labeled with α-hE-Sel and mIgG control using the 18 general procedure for enzymatic GF-IgG transfer. After that, the labeling detection and The one-pot product of CMP-Sialic acid conjugated mouse IgG (CS-mIgG) was then 8 incubated with NK-92 MI cells that express abundant terminal LacNAc units in the 9 presence of sialyltransferases (STs) (D). We tested three STs, including recombinant 10 ST6Gal1, Pasteurella multocida α(2,3) sialyltransferase M144D mutant (Pm2,3ST-11 M144D), Photobacterium damsel α(2,6) sialyltransferase (Pd2,6ST). According to the 12 results, all of these three enzymes could transfer CS-mIgG to cell surface (E and F). In 13 general, CS-Az-IgG is a more favorable substrate of these STs than CS-Poc-IgG. 14
ST6Gal1 is the most efficient ST in these three enzymes (E and F). Taken together, 15
ST6Gal1 and CS-Az-IgG is the best pair to transfer IgG to cell surface through sialylation 16
( Figure E) . This example demonstrates cell surface engineering through glycan to install 17 biomacromolecules could also be achieved using sialyltranferases. 
